U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time 'is not a crowd-pleaser,' Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. 'For those people who really aren't at risk ... I would recommend that they not take it.'